Huawei Qiu

2.1k total citations
39 papers, 1.1k citations indexed

About

Huawei Qiu is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Huawei Qiu has authored 39 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 16 papers in Radiology, Nuclear Medicine and Imaging and 13 papers in Oncology. Recurrent topics in Huawei Qiu's work include Monoclonal and Polyclonal Antibodies Research (15 papers), Glycosylation and Glycoproteins Research (8 papers) and Peptidase Inhibition and Analysis (5 papers). Huawei Qiu is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (15 papers), Glycosylation and Glycoproteins Research (8 papers) and Peptidase Inhibition and Analysis (5 papers). Huawei Qiu collaborates with scholars based in United States, France and China. Huawei Qiu's co-authors include Qun Zhou, Tim Edmunds, Heather Hughes, Clark Q. Pan, Scott Estes, Scott M. Van Patten, Anna Park, Ronnie R. Wei, H. Franklin Bunn and Ekaterina Boudanova and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Huawei Qiu

37 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Huawei Qiu United States 17 727 352 202 202 159 39 1.1k
Qun Zhou China 18 598 0.8× 484 1.4× 140 0.7× 173 0.9× 297 1.9× 36 1.1k
Jintang He United States 22 800 1.1× 201 0.6× 75 0.4× 178 0.9× 355 2.2× 40 1.3k
C. Kan United States 8 915 1.3× 151 0.4× 172 0.9× 266 1.3× 161 1.0× 11 1.3k
Shingo Kakita Japan 13 1.1k 1.5× 548 1.6× 57 0.3× 322 1.6× 99 0.6× 18 1.4k
Mohamed Amessou France 17 746 1.0× 112 0.3× 122 0.6× 345 1.7× 352 2.2× 33 1.6k
Hideo Ogiso Japan 14 1.1k 1.5× 459 1.3× 98 0.5× 93 0.5× 577 3.6× 23 1.6k
Finn C. Wiberg Denmark 21 1.3k 1.8× 174 0.5× 78 0.4× 201 1.0× 448 2.8× 32 2.1k
Subal Bishayee United States 18 837 1.2× 247 0.7× 99 0.5× 215 1.1× 302 1.9× 47 1.3k
Cecilia Chiu United States 16 1.1k 1.6× 132 0.4× 132 0.7× 143 0.7× 315 2.0× 19 1.7k
Gennadi V. Glinsky United States 18 1.3k 1.8× 172 0.5× 96 0.5× 571 2.8× 593 3.7× 22 1.9k

Countries citing papers authored by Huawei Qiu

Since Specialization
Citations

This map shows the geographic impact of Huawei Qiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huawei Qiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huawei Qiu more than expected).

Fields of papers citing papers by Huawei Qiu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huawei Qiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huawei Qiu. The network helps show where Huawei Qiu may publish in the future.

Co-authorship network of co-authors of Huawei Qiu

This figure shows the co-authorship network connecting the top 25 collaborators of Huawei Qiu. A scholar is included among the top collaborators of Huawei Qiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huawei Qiu. Huawei Qiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Park, Miso, Magali Pederzoli-Ribeil, Uğur Eskiocak, et al.. (2023). XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer. Journal for ImmunoTherapy of Cancer. 11(12). e007785–e007785. 8 indexed citations
2.
Wang, Caiyan, Chuang Wang, Huawei Qiu, et al.. (2023). Insight into the mechanism of Xiao–Chai–Hu–Tang alleviates irinotecan-induced diarrhea based on regulating the gut microbiota and inhibiting Gut β-GUS. Phytomedicine. 120. 155040–155040. 11 indexed citations
3.
Qiu, Huawei, Zeyun Li, Ying Wang, et al.. (2023). Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway. Phytomedicine. 121. 155093–155093. 12 indexed citations
4.
5.
Zhou, Qun, Ekaterina Boudanova, Jochen Beninga, et al.. (2020). Engineered Fc-glycosylation switch to eliminate antibody effector function. mAbs. 12(1). 1814583–1814583. 11 indexed citations
6.
Schmidt, Thorsten, Jochen Beninga, Huawei Qiu, et al.. (2020). Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models. mAbs. 12(1). 16 indexed citations
7.
Stefano, James E., Dana M. Lord, Joern Hopke, et al.. (2020). A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms. Journal of Biological Chemistry. 295(52). 18379–18389. 13 indexed citations
8.
Liu, Jie, et al.. (2020). Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer. SHILAP Revista de lepidopterología. 21(2). 198–207. 11 indexed citations
9.
Qiu, Huawei, Ronnie R. Wei, Ekaterina Boudanova, et al.. (2019). Engineering an anti-CD52 antibody for enhanced deamidation stability. mAbs. 11(7). 1266–1275. 16 indexed citations
10.
Boudanova, Ekaterina, Anna Park, Olivier Pasquier, et al.. (2019). Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life. mAbs. 11(7). 1276–1288. 73 indexed citations
11.
Lord, Dana M., et al.. (2018). Structure-based engineering to restore high affinity binding of an isoform-selective anti-TGFβ1 antibody. mAbs. 10(3). 444–452. 9 indexed citations
12.
Zhou, Qun & Huawei Qiu. (2018). The Mechanistic Impact of N-Glycosylation on Stability, Pharmacokinetics, and Immunogenicity of Therapeutic Proteins. Journal of Pharmaceutical Sciences. 108(4). 1366–1377. 112 indexed citations
13.
Sazinsky, Stephen L., Damian J. Houde, David J. DiLillo, et al.. (2017). Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs. Journal of Molecular Biology. 429(16). 2528–2541. 15 indexed citations
14.
Zhou, Yanfeng, et al.. (2016). Human acid sphingomyelinase structures provide insight to molecular basis of Niemann–Pick disease. Nature Communications. 7(1). 13082–13082. 38 indexed citations
15.
Stefano, James E., Julie Bird, Josephine Kyazike, et al.. (2012). High-Affinity VEGF Antagonists by Oligomerization of a Minimal Sequence VEGF-Binding Domain. Bioconjugate Chemistry. 23(12). 2354–2364. 9 indexed citations
16.
Wei, Ronnie R., Heather Hughes, Julie Bird, et al.. (2010). X-ray and Biochemical Analysis of N370S Mutant Human Acid β-Glucosidase. Journal of Biological Chemistry. 286(1). 299–308. 57 indexed citations
17.
Patten, Scott M. Van, Heather Hughes, Michael R. Huff, et al.. (2007). Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology. 17(5). 467–478. 88 indexed citations
18.
Zhou, Qun, Srinivas Shankara, André Roy, et al.. (2007). Development of a simple and rapid method for producing non‐fucosylated oligomannose containing antibodies with increased effector function. Biotechnology and Bioengineering. 99(3). 652–665. 149 indexed citations
19.
Qiu, Huawei, et al.. (1998). Homodimerization Restores Biological Activity to an Inactive Erythropoietin Mutant. Journal of Biological Chemistry. 273(18). 11173–11176. 29 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qun Zhou Breakdown of academic impact, for papers by Jintang He Breakdown of academic impact, for papers by C. Kan Breakdown of academic impact, for papers by Shingo Kakita Breakdown of academic impact, for papers by Mohamed Amessou Breakdown of academic impact, for papers by Hideo Ogiso Breakdown of academic impact, for papers by Finn C. Wiberg Breakdown of academic impact, for papers by Subal Bishayee Breakdown of academic impact, for papers by Cecilia Chiu Breakdown of academic impact, for papers by Gennadi V. Glinsky
Rankless by CCL
2026